By Princesster Aflakpui
Elon Musk’s brain-chip company Neuralink has been given a “Breakthrough Device” status by the U.S. Food and Drug Administration (FDA) for its experimental vision-restoring implant, Blindsight. This is a significant development for the field of neurotechnology. Musk claimed, in a tweet, that blindsight has the potential to help people who have lost both their eyes and their optic nerve regain their clarity of vision. As long as their visual cortex is unharmed, this ground-breaking technology may potentially enable people who have been blind from birth to see for the first time.
Musk foresees future capabilities that could surpass natural vision, including seeing in infrared, ultraviolet, and other wavelengths, even if the device’s initial vision will be low quality, similar to early video game visuals.
Neuralink is a revolutionary brain-computer interface (BCI) that promises to provide smooth brain-to-external device connection, opening up new possibilities for individuals with severe motor disabilities. A substantial advancement in this field of technology is the Blindsight gadget, which may provide those with severe visual impairments a new lease on life.
There is still cautious hope over the possible impact on blind people as research moves closer to clinical trials. Furthermore, developments in this field may open the door to additional breakthroughs in the fields of neuroprosthetics and brain-computer interfaces, which may have uses beyond vision restoration.
By Princesster Aflakpui
